Hansen Medical (HNSN) Misses Q3 EPS by 3c

Hansen Medical (NASDAQ: HNSN) reported Q3 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.7 million.

"During the third quarter, the Company expanded the body of clinical evidence for both the Magellan" Robotic System and the Sensei Robotic System as demonstrated by the results from the Barts Health NHS Trust study, the Imperial College study, and the first robot-assisted Uterine Fibroid Embolization procedure in the U.S.," said Cary Vance, Hansen Medical's Chief Executive Officer. "We believe demonstrating the breadth of capabilities of our robotic platforms through clinical validation will lead to optimal user experiences, increased utilization, and a higher value proposition."

For earnings history and earnings-related data on Hansen Medical (HNSN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Burry doubles down on Nebius short after stock surges 34% on earnings